# Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

> **NCT01853553** · PHASE3 · COMPLETED · sponsor: **University of Colorado, Denver** · enrollment: 61 (actual)

## Conditions studied

- ADPKD

## Interventions

- **DRUG:** Spironolactone
- **DRUG:** Sugar pill

## Key facts

- **NCT ID:** NCT01853553
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2017-01
- **Final completion:** 2017-01
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2019-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01853553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01853553, "Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01853553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*